default author photo

Koji Sasaki

University of Texas at Houston - Department of Leukemia

Houston, TX

United States

SCHOLARLY PAPERS

2

DOWNLOADS

157

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Combination of Oral Decitabine/Cedazuridine and Venetoclax in Patients with Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Number of pages: 30 Posted: 21 Sep 2023
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Miami - Sylvester Comprehensive Cancer Center, University of Texas at Houston - Section of Molecular Hematology and Therapy, Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 84 (777,583)

Abstract:

Loading...

myelodysplastic syndromes, MDS, oral decitabine, venetoclax, chronic myelomonocytic leukemia, CMML

2.

Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia

Number of pages: 45 Posted: 06 Dec 2022
University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - Department of Hematopathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Pharmacy, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Leukemia, University of California, Irvine - Chao Family Comprehensive Cancer Center, University of Texas at Houston - Department of Leukemia and University of Texas at Houston - Department of Leukemia
Downloads 73 (860,052)

Abstract:

Loading...

Philadelphia-negative ALL, inotuzumab, blinatumomab, chemo-immunotherapy, salvage, outcome